QR kód

Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism

Abstract Background Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may be more common than in noncancer patients. To evaluate our hypo...

Celý popis

Uloženo v:
Hlavní autoři: Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2025-04-01
Edice:Thrombosis Journal
Témata:
Factor Xa inhibitors
Anticoagulation effects
Cancer
Venous thromboembolism
On-line přístup:https://doi.org/10.1186/s12959-025-00720-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky